“The administration of a single dose of bone marrow– or adipose tissue–derived MSCs reduced continuous chronic alcohol intake by 50% during 10 days… Animals treated with MSCs significantly reduced up to 80–85% their relapse–like alcohol intake compared to control rats… significantly inhibited relapse–like drinking for the 40 days investigated, suggesting a protracted remodeling.”

“Transplantation of stem cells has shown promise for improving functional recovery for Alzheimer’s disease. MSCs could promote survival, increased the metabolic activity and help to rescue the AD (Alzheimer’s Disease) cell model in vitro.”

“Analysis of different indicators of chronic inflammation and aging included in initial, 24-hours, 2 weeks and 3 months protocols showed that stem cell treatment was safe for the patients; there were no adverse reactions. Moreover, data from follow-up protocols demonstrate significant improvement in energy level, hair, nail growth and skin conditions… Intravenously administered UC-MSCs were safe and effective in the improvement of symptoms related to chronic inflammation.”

“hMSC (human Mesenchymal Stem Cell) infusions decreased ECM (Extracellular Matrix) deposition as evidenced by decreases in soluble and insoluble collagen production… hMSCs participate in improved outcomes of remodeling by reversing excess collagen deposition and changing hyaluronan levels.”

“The combination of CBMNCs (Cord Blood Mononuclear Cells) and UCMSCs (Umbilical Cord Mesenchymal Stem Cells) showed larger therapeutic effects than the CBMNC transplantation alone… Compared with the Control group, both objective functional and subjective improvements were observed in visual, emotional and intellectual responses, body use, adaption to change, fear or nervousness, nonverbal communication and activity level assessed by CARS (Childhood Autism Rating Scale), as well as in lethargy/social withdrawal, stereotypic behavior, hyperactivity and inappropriate speech evaluated by ABC (Autism Behavior Checklist).”

“A single systemic injection of hMSCs (human Mesenchymal Stem Cells) into the tail vein was able to reduce NP-like behaviors and to modify molecular and cellular pain-associated pathways… hMSCs were able to reduce pain-like behaviors, such as mechanical allodynia and thermal hyperalgesia, once injected into the tail vein. An anti-nociceptive effect was detectable from day 11 post surgery (7 days post cell injection). hMSCs were mainly able to home in the spinal cord and pre-frontal cortex of neuropathic mice.”

“Autologous cell therapy in patients having chronic obstructive pulmonary disease is a safe procedure and free of adverse effects. There was an improvement in laboratory parameters (spirometry) and a slowing down in the process of pathological degeneration. Also, patients reported improvements in the clinical condition and quality of life.”

“After UC-MSC (umbilical cord mesenchymal stem cells) infusion, steroid dosage significantly decreased and the patients’ conditions were also improved significantly.”

“The results demonstrate the feasibility and safety of the allogeneic MSCs treatment while providing indications for their efficacy for relief of chronic low back pain… The procedure results in significant relief of pain and disability, and quantitative MRI evidence suggests partial disc healing.”

“A single treatment of hUCB-MSCs (human Umbilcial Cord Blood Mesenchymal Stem Cells) resulted in dose-dependent improvements in AD (Atopic Dermatitis) manifestation. Fifty-five percent of patients in high dose hUCB-MSC-treated group showed a 50% reduction in the EASI (Eczema Area and Severity Index) score… the administration of high dose hUCB-MSCs reduced the pruritus score by 58%.”

“Almost all of the studies reported improved erectile function in various animal models of CN (Cavernous Nerve) injury, vascular insufficiency, diabetes mellitus, hyperlipidemia, and aging… a single intracavernous injection of autologous ADSCs (Adipose-Derived Stem Cells) in 17 men (aged 46–69 years) with severe, refractory, post-prostatectomy ED resulting from surgery 5–18 months prior to enrollment… 8 of the 17 men recovered erectile function with the ability to accomplish sexual intercourse.”

“We have restored hearing in a 19-year-old white female with autoimmune hearing loss with
autologous adipose tissue derived stem cells… Systemic infusion of hASCs (human Adipose
tissue-derived Stem Cells) (in mouse model) significantly improved hearing function and
protected hair cells in established EAHL (Experimental Autoimmune Hearing Loss)… the
restoration is due to the paracrine activities of human stem cells, since there are newly
regenerated mice spiral ganglion cells, not human mesenchymal stem cells derived tissue
given intraperitoneally.”

“HUCB-derived MSCs have been shown to regenerate into cardiomyocytes in vitro… This
study supports IV administration as an adequate strategy for HUCB (Human Umbilical Cord
Blood) cell transplantation, allowing effective migration of the cells to the area of
injury where they subsequently induce autologous differentiation for repair of infarcted
myocardium.”

“Mesenchymal stem cells (MSC) are significantly renoprotective after ischemia-reperfusion
injury… MSC attached in the renal microvascular circulation significantly decreased
apoptosis of adjacent cells… These data demonstrate that the unique vasculotropic,
paracrine actions elicited by MSC play a significant renoprotective role after AKI (Acute
Kidney Injury).”

All patients were terminal state LC (Liver Cirrhosis) patients. Two third in 51 had the ascitis and more than one third had hepatic encephalopathy. After single stem cell therapy using UCBSC (Umbilical Cord Blood Stem Cell), most of the hepatic encephalopathy patients and more than two third of ascitic patients were improved in symptom or responded to medical therapy who were refractory to previous therapy… Stem cell therapy serves for prolongation of the life and improvement of quality of life.”

“Allogeneic UC MSCs (umbilical cord mesenchymal stem cells) were infused intravenously
on days 0 and 7… no transplantation-related adverse events were observed. 32.5% of
patients achieved MCR (major clinical response), 27.5% achieved PCR (partial clinical
response) during 12 months of follow up.”

“In the MSC-treated joints, there was marked regeneration of the medial meniscus and decreased cartilage destruction and bone changes.”

“Pooled results from 12 preclinical studies (110 animals in stem cell treatment groups, and 106 animals in control groups) indicated that stem cell based treatment was associated with significantly improved BMD (Bone Mass Density).”